DUBLIN – With Opdivo (nivolumab) about to cede leadership in the PD-1 inhibitor market to longtime rival Keytruda (pembrolizumab) today, the EMA's Committee on Human Medicinal Products (CHMP) did not pick a good time to refuse Bristol-Myers Squibb Co. an application for Opdivo plus low-dose Yervoy (ipilimumab) in first-line renal cell carcinoma (RCC).